Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $578
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. MDGL | 0.00 |
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:
MDGL) with a Buy and lowers the price target from $587 to $578.